Earnshaw J J, Scott D J, Horrocks M, Baird R N
Vascular Studies Unit, Bristol Royal Infirmary, UK.
Br J Surg. 1993 Jan;80(1):25-7. doi: 10.1002/bjs.1800800109.
Evidence has been accumulating that tissue plasminogen activator (tPA) is a more rapid and effective agent than streptokinase for peripheral thrombolysis. Twenty-three patients with acute limb-threatening ischaemia treated with tPA (0.5 mg h-1) over 15 months were compared with 20 consecutive patients previously receiving streptokinase (5000-10,000 units h-1). There were no major differences between the rates of complete and partial lysis (61 per cent for tPA versus 65 per cent for streptokinase) or limb salvage (65 versus 55 per cent respectively). Complication rates were also similar. It was not possible to show that tPA, an agent ten times more expensive than streptokinase, was superior for peripheral thrombolysis.
越来越多的证据表明,在进行外周溶栓时,组织型纤溶酶原激活剂(tPA)比链激酶起效更快且更有效。将15个月内接受tPA(0.5毫克/小时)治疗的23例急性肢体缺血濒临坏死患者与之前连续接受链激酶(5000 - 10000单位/小时)治疗的20例患者进行了比较。完全溶解和部分溶解率(tPA为61%,链激酶为65%)或肢体挽救率(分别为65%和55%)之间没有显著差异。并发症发生率也相似。无法证明比链激酶贵10倍的tPA在外周溶栓方面更具优势。